Summit Therapeutics (NASDAQ:SMMT – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Summit Therapeutics Stock Performance
NASDAQ:SMMT opened at $21.26 on Monday. The firm has a market cap of $15.40 billion, a price-to-earnings ratio of -92.43 and a beta of -0.97. The firm has a 50-day moving average price of $19.24 and a two-hundred day moving average price of $11.40. Summit Therapeutics has a 52 week low of $1.64 and a 52 week high of $33.89.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Summit Therapeutics
About Summit Therapeutics
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
See Also
- Five stocks we like better than Summit Therapeutics
- 10 Best Airline Stocks to Buy
- 3 Top Stocks It’s Not Too Late to Buy Today
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- ASML Stock Slides – A Buying Opportunity in Semiconductors?
- What is Forex and How Does it Work?
- 3 Stocks to Score from 40% YoY Data Center Capex Spending in 2025
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.